Keros Therapeutics
KROS
152 hedge funds and large institutions have $1.44B invested in Keros Therapeutics in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 64 increasing their positions, 40 reducing their positions, and 17 closing their positions.
1,935% more call options, than puts
Call options by funds: $1.75M | Put options by funds: $86K
60% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 40
35% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 17
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
3% more funds holding
Funds holding: 147 → 152 (+5)
0.03% more ownership
Funds ownership: 87.25% → 87.28% (+0.03%)
31% less capital invested
Capital invested by funds: $2.08B → $1.44B (-$640M)
Top Buyers
| 1 |
BlackRock
New York
|
+$18.7M |
| 2 |
JFG
Jefferies Financial Group
New York
|
+$14.3M |
| 3 |
Goldman Sachs
New York
|
+$14.1M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$13.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.4M |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$32.3M |
| 2 |
State Street
Boston,
Massachusetts
|
-$18.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.1M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$13.5M |
| 5 |
CWM
CIBC World Markets
New York
|
-$13.2M |
KROS Hedge Fund Activity: Q2 2024 in Review
152 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q2 2024, worth a combined $1.44B — down 31% from $2.08B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new KROS positions and 17 closed out — a net gain of 6 holders — while 64 added to existing stakes and 40 trimmed.
The largest buyer was BlackRock, adding an estimated $18.7M. The largest seller was Point72 Asset Management, cutting an estimated $32.3M.
- 152 institutional investors held Keros Therapeutics (KROS) as of Q2 2024, up from 147 in Q1 2024.
- Funds reported $1.44B of Keros Therapeutics stock for Q2 2024, down 31% quarter-over-quarter.
- 23 funds opened new Keros Therapeutics positions in Q2 2024 and 17 closed out, a net change of +6 holders.
- The largest Keros Therapeutics buyer in Q2 2024 was BlackRock, an estimated $18.7M added.
- The largest Keros Therapeutics seller in Q2 2024 was Point72 Asset Management, an estimated $32.3M sold.
Based on aggregated 13F filings for Q2 2024.